FDA Warns Against Counterfeit GLP-1 Receptor Agonists in Unauthorized Online Pharmacies
- The FDA issued an urgent safety alert on March 20, 2026, warning of counterfeit versions of semaglutide and tirzepatide circulating through unverified online retailers, with 47 adverse events reported including severe infections and allergic reactions.
- Counterfeit products lack sterility assurance and may contain contaminated ingredients or incorrect dosing, posing serious health risks to consumers seeking weight loss or diabetes treatment.
- The agency recommends patients obtain GLP-1 medications only through licensed pharmacies with valid prescriptions, emphasizing that legitimate suppliers require medical supervision.
Sources & Citations
1 sourceMore Stories
New Life Science Study Findings Recently Were Reported by Researchers at Johns Hopkins University Bloomberg School of Public Health (Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States): Life Science - Insurance News
• Researchers at the Johns Hopkins University Bloomberg School of Public Health published a new study on July 20, 2026, regarding formulary-related insurance denials for single-source branded drugs in the U.S. • The report highlights how drug utilization management tools, such as prior authorization, step therapy, and formulary exclusions, are used to reduce overall drug spending.
Read original · insurancenewsnet.comReal-world evidence and AI: How EHR data is reshaping drug development decisions
• AI tools utilizing Natural Language Processing (NLP) and Machine Learning (ML) are transitioning from pilot projects to routine use in drug development. • These technologies extract structured clinical data from unstructured Electronic Health Record (EHR) text, such as pathology reports and physician notes.
Read original · drugdiscoverynews.comHealth Bulletin 21/July/2026
• The Indian Health Ministry has approved Qdenga, a new dengue vaccine, following a comprehensive evaluation of its safety, quality, and efficacy. • The approval is based on a pivotal Phase III clinical trial conducted within India, as well as supporting studies from various dengue-endemic nations.
Read original · medicaldialogues.in
Medical DialoguesGilead to Present Twice-Yearly HIV Data at AIDS 2026
• Gilead Sciences will present clinical data for its HIV pre-exposure prophylaxis (PrEP) drug, lenacapavir, at the AIDS 2026 conference from July 26-31. • The data reveals high efficacy in two studies: PURPOSE 1 recorded zero new HIV infections, while PURPOSE 2 reported only one infection among participants continuing the treatment.
Read original · stocktitan.netHealth Matters newsletter: Health, politics and access - The Hindu
• Global health news was dominated by climate-linked crises, conflict, and infectious diseases, including a European heatwave linked to over 10,000 deaths. • Significant health threats emerged globally, including the first detection of H5 bird flu in New Zealand, an ongoing Ebola outbreak in Congo, and cyclosporiasis in the U.S.
Read original · thehindu.comNational COVID-19 trends, July 21 - The Sick Times
• Indicators suggest a summer COVID-19 wave is currently underway across the United States. • The South and West regions are showing the most definitive signals of increasing cases, though potential outbreaks are appearing nationwide.
Read original · thesicktimes.org
The Sick TimesHealth Bulletin 20/July/2026
• A NEET aspirant has alleged a major result discrepancy after their score plummeted from 609 to 167, highlighting ongoing concerns regarding OMR sheet errors. • A doctors' body is demanding a National Medical Commission (NMC) inquiry into the Sri Aurobindo Institute of Medical Sciences (SAIMS) in Indore.
Read original · medicaldialogues.in
Medical DialoguesHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
• Helus Pharma has completed enrollment ahead of schedule for the Phase 3 APPROACH study, which evaluates HLP003 as an adjunctive treatment for Major Depressive Disorder. • The company is continuing enrollment for EMBRACE, a second pivotal study within the Phase 3 PARADIGM Program, while rolling participants into the EXTEND study for long-term safety data.
Read original · investingnews.comHealth Matters newsletter: Health, politics and access - The Hindu
• Global health news this week was dominated by climate-linked crises, conflict, and infectious disease outbreaks. • An early European heatwave caused over 10,000 estimated deaths, with a significant spike in mortality reported in the Paris region.
Read original · thehindu.comPoynter’s PolitiFact launches service providing reliable, engaging health information to consumers and news organizations - Poynter
• PolitiFact, a project of the Poynter Institute, has launched "Well Informed," a new service designed to provide reliable health information to consumers and news organizations. • The initiative utilizes research-backed stories and social videos to help the public distinguish credible medical evidence from health-related misinformation.
Read original · poynter.org
PoynterAbortion pill access, THC sodas, cyclospora: Morning Rounds
• Morning Rounds reports on several diverse health and legal stories, including the current status of cyclospora outbreaks and the availability of THC-infused sodas in grocery stores. • The coverage also highlights a specific criminal case involving a fugitive in Rhode Island who maintained a double life.
Read original · statnews.com
StatnewsRare disease biotechs lobby Trump, PBMs skirt state laws
• Rare disease biotechnology companies are lobbying the Trump administration to prevent the implementation of Medicare price caps on their medications. • Pharmacy Benefit Managers (PBMs) are reportedly bypassing state laws designed to regulate their practices and pricing structures.
Read original · statnews.com
Statnews